Abstracts tagged "pain"

Abstract Number: 1790 • ACR Convergence 2025
Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
Lai Wang¹, alia obeidat², Shingo Ishihara³, Jun Li², Frank Ko², Terese Geraghty², Natalie Adamczyk³, Sarah Soorya², Richard Miller⁴, Rachel Miller¹ and Anne-Marie Malfait², ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, ³Rush University, Chicago, ⁴Northwestern University, Chicago
Background/Purpose: Nociceptors abundantly innervate the knee joint. In experimental osteoarthritis (OA), nociceptors sprout in the medial synovium and in subchondral bone channels. We aimed to…
Abstract Number: 1278 • ACR Convergence 2025
Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Emily Masi¹, Kimberly Rapoza², Tamar Rubinstein³, Kathy Kenney-Riley⁴ and Joyce Hui-Yuen⁵, ¹Cohen Children's Medical Center, North New Hyde Park, NY, ²Mercy College, Dobbs Ferry, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Mercy University, Dobbs Ferry, NY, ⁵North Shore LIJ Health System, Great Neck, NY
Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…
Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Jerik Leung¹, Tomika Caldwell², Paul Nietert³, Clara Dismuke⁴, Hetlena Johnson⁵, Edith Williams⁶ and Everette Keller³, ¹Emory University, Rollins School of Public Health, Atlanta, GA, ²Medical University of Souty Carolina, Charleston, ³Medical University of South Carolina, Charleston, SC, ⁴VA Palo Alto Health Care System, Menlo Park, ⁵Lupus Community Advocate/Researcher, Columbia, SC, ⁶University of Rochester Medical Center, Rochester, NY
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…
Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Sachalee Campbell¹, Laura Daniel², Puran Nepa², Otis Wilson³, Alyson L. Dickson³, Katherine Murray³, William D. Dupont³, Adriana Hung³, Wayne A. Ray³, Michael Stein⁴ and Cecilia P. Chung², ¹University of Miami, Miami, FL, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³Vanderbilt University Medical Center, Vanderbilt, TN, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Philip Conaghan¹, nathaniel katz², Asger Bihlet³, Laus W Wullum⁴, Kerry af Forselles⁵, C Michael Perkins⁵, Bernadette Hughes⁶, Claire Herholdt⁷ and Iwona Bombelka⁸, ¹University of Leeds, Leeds, United Kingdom, ²Rin Sof Innovation, Ltd, Boston, MA, ³NBCD A/S, Herlev, Denmark, ⁴Omicron A/S, Copenhagen, Denmark, ⁵Levicept, Sandwich, United Kingdom, ⁶Levicept, Ashtead, United Kingdom, ⁷Levicept Ltd, Ashtead, United Kingdom, ⁸Levicept, Sandwich, Kent, United Kingdom
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…
Abstract Number: 1780 • ACR Convergence 2025
Modeling Osteoarthritis Knee Joint in a Compartmentalized Microfluidic System using IPSC-derived Sensory Neurons and human Synovial Fibroblasts
Abdelhak Belmadani¹, Dongjun Ren¹, Daniel Hoffman², Nirupa Jayraj¹, Paola Pacifico¹, Vince Truong³, Patrick Walsh³, Daniela Menichella¹, Anna Rapp⁴, Carla Scanzello⁵, Rachel Miller⁶, Richard Miller⁷ and Anne-Marie Malfait⁸, ¹Northwestern University Chicago, Chicago, IL, ²Rush University, Chicago, IL, ³Anatomic Inc, Minneapolis, MN, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, ⁶Rush University Medical Center, Chicago, IL, ⁷Northwestern University, Chicago, ⁸Rush University Medical Center, Chicago
Background/Purpose: Joint pain is one of the most significant clinical hallmarks of knee osteoarthritis (OA). Knee OA is a chronic degenerative disease of the joints…
Abstract Number: 1257 • ACR Convergence 2025
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Puneet Bajaj², Urooj Wahid², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Rheumatic diseases (RD) often cause pain, fatigue and disability. Depression and anxiety are prevalent comorbidities in RD and ideally managed with behavioral health (BH)…
Abstract Number: 1230 • ACR Convergence 2025
Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
Gillian Fennell¹, Sarah Tilley², Sayali Dhamne³, Robert Edwards⁴, Mary Gheller³, Angelo Demalia³, Margaret Clancy³, Michael LaValley⁵, Emelia J Benjamin³ and Tuhina Neogi⁶, ¹Boston University Medical, Boston, MA, ²Boston University School of Medicine, Somerville, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Brigham and Women's Hospital & Harvard Medical School, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Over a third of older Americans experience chronic pain, typically occupying multiple musculoskeletal body sites. While number of pain sites (NPS) is often touted…
Abstract Number: 0817 • ACR Convergence 2025
More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Patients with rheumatic diseases commonly experience acute or chronic pain that may lead to both short- and long-term opioid use. Many patients do not…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: 2098 • ACR Convergence 2025
Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Natalie Keller¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁶, Criswell Lavery⁸, Bibiana Ateh⁹, Bridget Kramer², Kimberly Hayes⁶, Rui Xiao⁸, Kaitian Jin⁸, Alexis Ogdie⁸, Daniel K. White¹⁰, Tuhina Neogi¹¹, Carla Scanzello¹² and Joshua Baker⁸, ¹University of Oklahoma, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Howard University Hospital and Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, ⁵Brown University, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Washington VA Medical Center, Washington, District of Columbia, ¹⁰University of Delaware, Newark, DE, ¹¹Boston University School of Medicine, Boston, MA, ¹²University of Pennsylvania, Philadelphia
Background/Purpose: Intra-articular (IA) corticosteroid injections are commonly utilized for pain management in knee osteoarthritis (KOA). However, clinical characteristics associated with a greater benefit from corticosteroid…
Abstract Number: 1739 • ACR Convergence 2025
Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
Michael Newton¹, Lai Wang², Anne-Marie Malfait³, Rachel Miller² and Tristan Maerz⁴, ¹University of Michigan, South Lyon, MI, ²Rush University Medical Center, Chicago, IL, ³Rush University, Oak Park, IL, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: In arthritic synovium, emerging clinical evidence suggests crosstalk between synovial cells and dorsal root ganglion (DRG) neurons drives nerve sprouting and pain sensitization [Bai+…
Abstract Number: 1256 • ACR Convergence 2025
Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Urooj Wahid², Puneet Bajaj², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Patients with rheumatic diseases (RD) often experience chronic pain, along with comorbid depression and anxiety, which can be addressed using behavioral health (BH) interventions…
Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Gregory Sullivan¹, Errol Gould², Mary Kelley¹, Jean Engels¹ and Seth Lederman³, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceutical, Inc., Henderson, NV, ³Tonix Pharmaceuticals, Inc., Austin, TX
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].